Research programme: MHC class II gene modulators - Debiopharm

Drug Profile

Research programme: MHC class II gene modulators - Debiopharm

Alternative Names: Debio 0406; p53-69

Latest Information Update: 14 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GPC Biotech AG
  • Developer Debiopharm
  • Class Small molecules
  • Mechanism of Action MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2007 Preclinical development is ongoing
  • 17 Dec 2004 GPC Biotech's small molecule MHC class II antagonists programme has been licensed to Debiopharm worldwide
  • 29 Aug 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top